Core Insights - NAYA Biosciences is expanding its bifunctional antibody pipeline to include a novel PD-1 x VEGF tetravalent bifunctional antibody for treating hepatocellular carcinoma (HCC) and other solid tumors [1][4] Company Overview - NAYA Biosciences is a life science portfolio company focused on breakthrough treatments in oncology, autoimmune diseases, and women's health [5] - The company utilizes a hub & spoke model to efficiently acquire, develop, and partner assets, optimizing return on investment through scalable and profitable commercial revenues [5] Product Development - The new PD-1 x VEGF antibody, named NY-500, is designed to synergistically target PD-1 and VEGF, potentially improving T-cell infiltration and immune response in tumors [4] - NAYA is also developing NY-303, a GPC3-targeting bifunctional antibody, currently in a phase 1/2 clinical trial for HCC patients who do not respond to existing therapies [3][6] - NY-500 is expected to enter monotherapy phase 1/2a clinical trials in early 2026 [4][7] Market Potential - The PD-(L)1 market is projected to exceed $50 billion in 2025, indicating significant growth opportunities for NAYA's therapeutic candidates [4]
NAYA Biosciences Announces Development of NY-500, a Novel AI-Optimized PD-1 x VEGF Bifunctional Antibody